Recorlev (levoketoconazole) is an FDA-approved oral medication for controlling cortisol excess in adults with endogenous Cushing's syndrome. It is a refined, more selective form of ketoconazole โ a steroidogenesis inhibitor that blocks multiple enzymes in the cortisol synthesis pathway. Recorlev was specifically developed to retain the cortisol-lowering efficacy of ketoconazole while reducing its liver toxicity and other off-target effects.
๐ง Cushing's Syndrome Care: Our endocrinologists manage the full workup and treatment of Cushing's syndrome, including prescribing and monitoring Recorlev. Call 832-968-7003 to schedule an evaluation.
What Is Endogenous Cushing's Syndrome?
Endogenous Cushing's syndrome occurs when the body overproduces cortisol from within โ as opposed to iatrogenic Cushing's from external steroid use. Causes include:
- Cushing's disease (most common): ACTH-secreting pituitary adenoma
- Ectopic ACTH syndrome: ACTH-secreting tumor elsewhere (e.g., lung, thymus)
- Adrenal tumor: Adrenal adenoma or carcinoma producing cortisol directly (ACTH-independent)
Recorlev is approved for all three forms of endogenous Cushing's syndrome โ not just Cushing's disease. This broad indication distinguishes it from Isturisa, which is approved only for Cushing's disease.
How Recorlev Works
Recorlev is the pure (2S,4R) enantiomer of ketoconazole. It blocks several key enzymes in the adrenal cortisol production pathway:
- CYP11A1 (cholesterol side-chain cleavage)
- CYP11B1 (11ฮฒ-hydroxylase) โ same enzyme targeted by Isturisa
- CYP17A1 (17ฮฑ-hydroxylase)
By blocking multiple steps in cortisol synthesis, Recorlev reduces cortisol production from both ACTH-dependent and ACTH-independent pathways, making it effective across all etiologies of endogenous Cushing's.
Clinical Evidence โ LOGICS and SONICS Trials
The pivotal Phase 3 program (LOGICS randomized withdrawal + SONICS open-label) demonstrated:
- ~30% of patients achieved mean urinary free cortisol (UFC) normalization by end of titration
- Significant improvements in blood pressure, fasting glucose, body weight, and quality of life
- LOGICS randomized withdrawal: patients who continued Recorlev maintained cortisol control significantly better than those switched to placebo
- Mean UFC decreased from approximately 3ร ULN at baseline to within normal range in responders
Dosing & Administration
- Route: Oral tablet, taken twice daily (approximately 12 hours apart)
- Starting dose: 150 mg twice daily
- Titration: Increased by 150 mg increments every 2โ3 weeks based on UFC response, to a maximum of 600 mg twice daily (1,200 mg/day total)
- Target: Mean UFC within normal range without causing adrenal insufficiency
- Monitoring: UFC every 2โ4 weeks during titration; then every 1โ3 months when stable
Side Effects & Safety
| Side Effect | Frequency | Notes |
|---|---|---|
| Adrenal insufficiency | Significant risk with over-suppression | Monitor for fatigue, nausea, dizziness, hypotension โ may require dose reduction or temporary steroid replacement |
| Hepatotoxicity (liver injury) | Boxed warning โ rare but serious | LFTs required before starting, monthly for first 6 months, then quarterly. Discontinue if ALT/AST rises significantly |
| QT prolongation | Boxed warning | EKG monitoring required; avoid concurrent QT-prolonging medications |
| Nausea, vomiting, abdominal discomfort | Common (~35โ40%) | Usually manageable; taking with food helps |
| Hypokalemia | Common | Monitor potassium; supplement as needed |
| Peripheral edema | Common | Usually mild |
| Gynecomastia / testosterone reduction | Men (~15%) | Due to androgen synthesis inhibition |
| Menstrual irregularities | Women | Due to effects on sex steroid synthesis |
โ ๏ธ Boxed Warnings: Recorlev carries boxed warnings for hepatotoxicity and QT prolongation. Liver function tests and EKGs must be performed before starting and monitored throughout treatment. These risks were also present with the parent drug ketoconazole โ Recorlev's improved selectivity reduces but does not eliminate them.
REMS Program
Like other Cushing's medications, Recorlev is available through a Risk Evaluation and Mitigation Strategy (REMS) program due to its liver toxicity and cardiac risks. Prescribers, pharmacies, and patients must be enrolled in the REMS. Our office handles enrollment and monitoring coordination.
Drug Interactions
- Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole) โ increase Recorlev levels; avoid or adjust dose
- Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) โ reduce Recorlev levels; avoid
- QT-prolonging drugs โ additive risk; review all medications carefully
- Statins metabolized by CYP3A4 (simvastatin, lovastatin) โ increased statin exposure; use with caution or switch to non-CYP3A4 statin (e.g., rosuvastatin)
- Warfarin โ increased anticoagulant effect; close INR monitoring
Comparing Cushing's Medications
| Drug | Mechanism | Approved Etiology | Key Safety Concern |
|---|---|---|---|
| Recorlev (levoketoconazole) | Multi-enzyme steroidogenesis inhibitor | All endogenous Cushing's | Hepatotoxicity, QT prolongation |
| Isturisa (osilodrostat) | 11ฮฒ-hydroxylase inhibitor | Cushing's disease only (pituitary) | Adrenal insufficiency, QT, androgens |
| Korlym (mifepristone) | Glucocorticoid receptor blocker | Cushing's + T2D/glucose intolerance | Adrenal insufficiency (undetectable), endometrial effects |
| Signifor (pasireotide) | Somatostatin analogue | Cushing's disease (pituitary) | Severe hyperglycemia |
Key Takeaways
- Recorlev is an oral, twice-daily cortisol synthesis inhibitor approved for all forms of endogenous Cushing's syndrome
- Refined version of ketoconazole with improved selectivity โ same mechanism, reduced off-target effects
- Broad indication: works for Cushing's disease, ectopic ACTH, and adrenal tumors
- Boxed warnings for hepatotoxicity and QT prolongation โ liver enzymes and EKG required
- UFC is monitored to guide dosing (unlike Korlym, where cortisol levels cannot be used)
- Available through REMS program; our office coordinates enrollment and monitoring
Our Team Treats Adrenal Disorders
All five of our providers evaluate and manage adrenal and endocrine conditions. Book with any member of our team:
Book an Appointment โ or call 832-968-7003